Differential diagnostic performance of a panel of plasma biomarkers for different types of dementia

INTRODUCTION: We explored what combination of blood‐based biomarkers (amyloid beta [Aβ](1‐42/1‐40), phosphorylated tau [p‐tau]181, neurofilament light [NfL], glial fibrillary acidic protein [GFAP]) differentiates Alzheimer's disease (AD) dementia, frontotemporal dementia (FTD), and dementia with Lewy bodies (DLB). METHODS: We measured the biomarkers with Simoa in two separate cohorts (n = 160 and n = 152). In one cohort, Aβ(1‐42/1‐40) was also measured with mass spectrometry (MS). We assessed the differential diagnostic value of the markers, by logistic regression with Wald's backward selection. RESULTS: MS and Simoa Aβ(1‐42/1‐40) similarly differentiated AD from controls. The Simoa panel that optimally differentiated AD from FTD consisted of NfL and p‐tau181 (area under the curve [AUC] = 0.94; cohort 1) or NfL, GFAP, and p‐tau181 (AUC = 0.90; cohort 2). For AD from DLB, the panel consisted of NfL, p‐tau181, and GFAP (AUC = 0.88; cohort 1), and only p‐tau181 (AUC = 0.81; cohort 2). DISCUSSION: A combination of plasma p‐tau181, NfL, and GFAP, but not Aβ(1‐42/1‐40), might be useful to discriminate AD, FTD, and DLB.